$ETRA SEC Filings

Filed On	Filing
28 Sep 2026	SCHEDULE 13G
28 Sep 2026	SCHEDULE 13G
25 Sep 2026	SCHEDULE 13D
23 Sep 2026	Form 4: Gordon Carl L, Director Received 5,551,837 shares by conversion · Bought 1,333,333 shares ($20M)
23 Sep 2026	Form 4: Orbimed Advisors Llc, Director and 2 others Received 5,551,837 shares by conversion · Bought 1,333,333 shares ($20M)
21 Sep 2026	Form 3: Westlake BioPartners Fund I, L.p., 10% owner and 3 others Holds 3,527,136 shares of Common Stock
21 Sep 2026	Form 4: Parry Graham, Chief Scientific Officer Received 85,504 shares by conversion
21 Sep 2026	Form 4: Koe Gary S., Chief Technical Officer Received 63,656 shares by conversion
21 Sep 2026	Form 4: Dong Quehuong (Kathy), Director Received 455,484 shares by conversion
21 Sep 2026	Form 4: Stagliano Nancy, Director Received 255,635 shares by conversion
21 Sep 2026	S-8
21 Sep 2026	8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Other Events Electra Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that:
18 Sep 2026	Form 3: Clark Christopher William, Chief Financial Officer
18 Sep 2026	Form 3: Tucker David J., Principal Accounting Officer
18 Sep 2026	Form 3: Parry Graham, Chief Scientific Officer
18 Sep 2026	Form 3: Parry Graham, Principal Accounting Officer
18 Sep 2026	Form 3: Koe Gary S., Chief Technical Officer
18 Sep 2026	Form 3: Dong Quehuong (Kathy), Director
18 Sep 2026	Form 3: Dao Kim-Hien, Chief Medical Officer
18 Sep 2026	Form 3: Stagliano Nancy, Director

Comments